...
首页> 外文期刊>Rejuvenation research >Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.
【24h】

Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.

机译:雷帕霉素作为抗衰老治疗药物:以雷帕霉素为哺乳动物靶标,可治疗Hutchinson-Gilford早衰症和神经退行性疾病。

获取原文
获取原文并翻译 | 示例

摘要

Mammalian target of rapamycin (mTOR), a serine/threonine kinase and component of the mTORC1 signaling complex, acts as an energy, nutrient, growth factor, stress, and redox sensor to increase protein synthesis and decrease macroautophagy. mTORC1 plays a central role in the maintenance of homeostasis and its deterioration, seen in aging. The Food and Drug Administration (FDA)-approved immunosuppressive macrolide rapamycin binds immunophilin FKBP12 (FK506-binding protein) to inhibit mTORC1. Unlike most other interventions tested to date, inhibition of mTORC1 by rapamycin extends life span in old mice, likely by a combination of increased autophagy and decreased mRNA translation. Hutchinson-Gilford progeria syndrome (HGPS) is a lethal genetic disorder affecting children that is characterized by symptoms of premature aging, such as atherosclerosis. Increased autophagy induced by rapamycin reduces accumulation of progerin, an alternate spliced form of lamin A/C, that forms insoluble toxic aggregates, resulting in reduced HGPS-associated nuclear blebbing, growth inhibition, epigenetic dysregulation, and genomic instability. Rapamycin-induced autophagy also suppresses symptoms in mouse models of Alzheimer, Parkinson, and Huntington diseases, where toxic insoluble protein aggregates accumulate. On the basis of these results, modulation of mTORC1 function is a promising target for the development of therapeutics for neurodegenerative diseases and HGPS. Rapamycin is the obvious candidate for near-term evaluation in the treatment of these diseases. However, the substantial set of rapamycin-associated adverse effects, as well as the lack of aging-specific human data, should caution the routine use of rapamycin as an antiaging agent. The use of safer, but perhaps weaker, indirect mTORC1 inhibitors, such as metformin and resveratrol, may prove useful. Further study will ascertain whether such compounds extend human health or life span.
机译:雷帕霉素(mTOR)的哺乳动物靶标是一种丝氨酸/苏氨酸激酶,是mTORC1信号复合物的组成部分,可作为能量,营养素,生长因子,压力和氧化还原传感器,以增加蛋白质合成并减少宏观自噬。 mTORC1在维持体内稳态及其衰老中起着核心作用。美国食品药品监督管理局(FDA)批准的免疫抑制大环内酯雷帕霉素结合亲免蛋白FKBP12(FK506结合蛋白)来抑制mTORC1。与迄今测试的大多数其他干预措施不同,雷帕霉素对mTORC1的抑制作用可能会延长自噬和降低mRNA翻译,从而延长了老年小鼠的寿命。 Hutchinson-Gilford早衰综合症(HGPS)是一种影响儿童的致命遗传性疾病,其特征是过早衰老的症状,例如动脉粥样硬化。雷帕霉素诱导的自噬的增加减少了progerin的积累,progerin是lamin A / C的另一种剪接形式,形成不溶的有毒聚集体,从而减少了与HGPS相关的核起泡,生长抑制,表观遗传失调和基因组不稳定。雷帕霉素诱导的自噬还可以抑制阿尔茨海默氏症,帕金森氏症和亨廷顿氏症的小鼠模型中的症状,这些模型中会聚集有毒的不溶性蛋白质。基于这些结果,mTORC1功能的调节是神经退行性疾病和HGPS治疗药物开发的有希望的目标。雷帕霉素显然是这些疾病近期评估的候选者。但是,雷帕霉素相关的大量不良反应以及缺乏特定于衰老的人类数据,应提醒雷帕霉素作为抗衰老剂的常规使用。使用更安全但可能更弱的间接mTORC1抑制剂(如二甲双胍和白藜芦醇)可能被证明是有用的。进一步的研究将确定这些化合物是否延长人类健康或寿命。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号